Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is June 03, 2024.
All times in Eastern Daylight Time.
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ CommunityNEW YORK--(BUSINESS WIRE)--Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and the organization’s mission to accelerate acceptance for the LGBTQ+ community. In the... more »
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol AmendmentCAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced ... more »
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual MeetingNEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from... more »
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study o... more »
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerPRINCETON, N.J.--(BUSINESS WIRE)--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced.... more »
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaOSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive resul... more »
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024CHICAGO--(BUSINESS WIRE)--ASCO Annual Meeting – Massive Bio, pioneering leader in AI-driven oncology solutions, is excited to announce the launch of its latest product, Drug Utilization Optimizer (... more »
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersFOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Ar... more »
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMAMIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a manuscript title... more »
-
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Ar... more »
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with len... more »
-
Guidewire gratuluje zwycięzcom pierwszego wirtualnego hackathonu DEVHackSAN MATEO, Kalifornia--(BUSINESS WIRE)--Guidewire (NYSE: GWRE) gratuluje zwycięzcom wydarzenia DEVHack 2024, pierwszego wirtualnego hackathonu Guidewire opracowanego w celu zaangażowania największe... more »
-
The World's Light Painting Masters and GAC Work Together to Create a Chinese Giant Light-Painted Dragon That Shines in Dubai for the First TimeGUANGZHOU, China--(BUSINESS WIRE)--Coinciding with the Chinese Year of the Dragon in 2024, in order to celebrate the 40th anniversary of the establish diplomatic relations between China and UAE, th... more »
-
アダニ・ポーツ、ダルエスサラーム港第2コンテナターミナルの運営に関する期間30年のコンセッション契約を締結インド・アーメダバード & アラブ首長国連邦アブダビ--(BUSINESS WIRE)--(ビジネスワイヤ) -- アダニ・ポーツ・アンド・スペシャル・エコノミック・ゾーン (APSEZ)の100%親会社であるアダニ・インターナショナル・ポーツ・ホールディングス(AIPH)は、タンザニアのダルエスサラーム港の第2コンテナターミナルを運営・管理するために、タンザニア港湾局と30年間のコンセッシ... more »
-
Adani Ports簽署三蘭港2號貨櫃碼頭30年特許經營合約印度阿默達巴德和阿拉伯聯合大公國阿布達比--(BUSINESS WIRE)--(美國商業資訊)-- Adani Ports and Special Economic Zone Ltd. (APSEZ)的全資子公司Adani International Ports Holdings Pte Ltd. (AIPH)與坦尚尼亞港務局簽署了為期30年的特許經營協議,負責營運和管理三蘭港2號貨櫃碼頭。... more »